Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Signaling

Background:

• Epidermal growth factor (EGF)-like ligands exhibit high selectivity for ErbB receptors.
• Both linear regions of EGF-like ligands are crucial for determining receptor selectivity.
• Previous studies demonstrated independent optimization of ligand regions for enhanced affinity.

Purpose of the Study:

• To engineer an EGF mutant with broadened ErbB binding specificity, targeting ErbB3.
• To investigate the binding and activation characteristics of the engineered EGF mutant on ErbB1 and ErbB3 receptors and their heterodimers.

Main Methods:

• Site-directed mutagenesis of EGF to introduce ErbB3 binding motifs in N- and C-terminal regions.
• Generation of EGF mutant WVR/EGF/IADIQ.
• Analysis of receptor binding affinity and activation using cell-based assays, including cell survival and receptor phosphorylation.
• Assessment of ErbB1.ErbB3 heterodimer activation.

Main Results:

• The EGF mutant WVR/EGF/IADIQ demonstrated high affinity for ErbB3.
• The mutant activated ErbB3 through ErbB2.ErbB3 heterodimers, mimicking NRG1beta.
• The mutant retained full capacity to bind and activate ErbB1.
• Despite high affinity for both ErbB1 and ErbB3, the mutant failed to activate ErbB1.ErbB3 heterodimers.

Conclusions:

• High-affinity binding to both ErbB1 and ErbB3 is achievable and not mutually exclusive.
• The engineered EGF mutant provides a tool for structural comparison of ErbB1 and ErbB3 ligand-binding properties.
• This study demonstrates the potential for creating novel ligands with tailored dual-specificity for ErbB receptors.